The first virtual ASCO meeting; plus Part 2 of tech tools for docs
04/30/20 • 37 min
The American Society of Clinical Oncology is gearing up for its first-ever virtual meeting at the end of May 2020. ASCO’s president Howard A. “Skip” Burris, III, MD, joins David H. Henry, MD, of Pennsylvania Hospital, Philadelphia, to explain how the virtual meeting will work, from releasing research to earning continuing medical education credits. Dr. Burris also explores how the society is responding to COVID-19.
Later in the podcast, Bernard A. Mason, MD, an oncologist with Pennsylvania Hospital and the University of Pennsylvania, both in Philadelphia, is back with some bonus technology tips for taking notes and syncing them across devices, sharing large files, and best practices for backing up files.
Disclosures:
Dr. Henry reported having no financial disclosures relevant to this episode.
Dr. Burris has a full list of his financial disclosures here.
Dr. Mason reported having no financial disclosures relevant to this episode.
* *
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: [email protected]
Interact with us on Twitter: @MDedgehemonc
David Henry on Twitter: @davidhenrymd
Ilana Yurkiewicz on Twitter: @ilanayurkiewicz
The American Society of Clinical Oncology is gearing up for its first-ever virtual meeting at the end of May 2020. ASCO’s president Howard A. “Skip” Burris, III, MD, joins David H. Henry, MD, of Pennsylvania Hospital, Philadelphia, to explain how the virtual meeting will work, from releasing research to earning continuing medical education credits. Dr. Burris also explores how the society is responding to COVID-19.
Later in the podcast, Bernard A. Mason, MD, an oncologist with Pennsylvania Hospital and the University of Pennsylvania, both in Philadelphia, is back with some bonus technology tips for taking notes and syncing them across devices, sharing large files, and best practices for backing up files.
Disclosures:
Dr. Henry reported having no financial disclosures relevant to this episode.
Dr. Burris has a full list of his financial disclosures here.
Dr. Mason reported having no financial disclosures relevant to this episode.
* *
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: [email protected]
Interact with us on Twitter: @MDedgehemonc
David Henry on Twitter: @davidhenrymd
Ilana Yurkiewicz on Twitter: @ilanayurkiewicz
Previous Episode
Treating colorectal cancer in the COVID-19 era
Oncologists are now weighing the benefits of treating cancer patients against the risk of exposing them to SARS-CoV-2. David Kerr, MD, DSc, of University of Oxford (England) talks with podcast host David H. Henry, MD, of Pennsylvania Hospital in Philadelphia, about how to treat colorectal cancer patients in the COVID-19 era.
Dr. Kerr cowrote an article on MDedge Hematology/Oncology that outlined recommendations for treating colorectal cancer patients during the pandemic. In this episode, Dr. Henry and Dr. Kerr review those recommendations and compare notes on U.K. and U.S. practices.
Disclosures:
Dr. Henry reported having no financial disclosures relevant to this episode. Dr. Kerr has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers.
* *
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: [email protected]
Interact with us on Twitter: @MDedgehemonc
David Henry on Twitter: @davidhenrymd
Ilana Yurkiewicz on Twitter:@ilanayurkiewicz
Next Episode
Treating genitourinary malignancies in the COVID-19 era
How should oncologists be treating genitourinary malignancies during the COVID-19 pandemic? Aly-Khan A. Lalani, MD, of McMaster University in Hamilton, Ontario, and colleagues recently published recommendations that help answer that question (Can Urol Assoc J. 2020 May;14[5]:e154-8).
In this episode, Dr. Lalani reviews some of these recommendations with podcast host David H. Henry, MD, of Pennsylvania Hospital in Philadelphia. The pair discuss when and how to use androgen receptor axis-targeted therapies and radium-223 in metastatic prostate cancer, platinum-based chemotherapy in advanced urothelial carcinoma, and checkpoint inhibitors in patients with urothelial carcinoma or renal cell carcinoma.
* *
Disclosures:
Dr. Henry reported having no financial disclosures relevant to this episode.
Dr. Lalani has relationships with Astellas Pharma, Bayer, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Roche/Genentech, TerSera, AbbVie, Eisai, Ipsen, and Janssen.
* *
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: [email protected]
Interact with us on Twitter: @MDedgehemonc
David Henry on Twitter: @davidhenrymd
Ilana Yurkiewicz on Twitter: @ilanayurkiewicz
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/blood-and-cancer-197219/the-first-virtual-asco-meeting-plus-part-2-of-tech-tools-for-docs-19337341"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to the first virtual asco meeting; plus part 2 of tech tools for docs on goodpods" style="width: 225px" /> </a>
Copy